Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Weighted Average) (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Shares Outstanding (Weighted Average) data on record, last reported at $58.6 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 10.61% year-over-year to $58.6 million; the TTM value through Sep 2025 reached $58.6 million, up 10.61%, while the annual FY2024 figure was $54.0 million, 22.76% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $58.6 million in Q3 2025 per STOK's latest filing, up from $58.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $58.6 million in Q3 2025 and bottomed at $37.4 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 4 years is $47.6 million, with a median of $44.3 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 26.2% in 2024, then increased 4.2% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $38.9 million in 2022, then increased by 13.1% to $44.0 million in 2023, then grew by 22.76% to $54.0 million in 2024, then rose by 8.52% to $58.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $58.6 million in Q3 2025, $58.1 million in Q2 2025, and $57.9 million in Q1 2025.